A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Safety, Pharmacokinetics, and Efficacy of HSK21542 Injection in Subjects Undergoing Hemodialysis

Haisco Pharmaceutical Group Co., Ltd.1 site in 1 country131 target enrollmentAugust 10, 2020

DrugsStage I:HSK21542 0.05 μg/kg Stage I:HSK21542 0.15 μg/kg Stage I:HSK21542 0.30 μg/kg Stage I:HSK21542 0.80 μg/kg Stage II:HSK21542 0.3 μg/kg Stage II:HSK21542 0.6 μg/kg

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Uremic Pruritus
Sponsor: Haisco Pharmaceutical Group Co., Ltd.
Enrollment: 131
Locations: 1
Primary Endpoint: Stage II：At week 12, the change in weekly average of daily Worst Itch NRS (WI-NRS) from baseline in subjects undergoing hemodialysis
Status: Completed
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This is a multi-center, randomized, double-blind, placebo-controlled phase II clinical trial. The main objective is to evaluate the safety, pharmacokinetics, and efficacy of HSK21542 injection in subjects undergoing hemodialysis

Detailed Description

This study is a multicenter study, which is divided into two stages. The first stage is a dose escalation, randomized, double-blind, placebo-controlled study of multiple intravenous administration within one week in hemodialysis subjects. The second stage is a randomized, double-blind, placebo-controlled study of Administration for 12 weeks in hemodialysis subjects with moderate or severe pruritus. In the second stage, consist of a Screening Visit, a 7-day Run-in Period, a 12 week Double-blind Treatment Period, and a 2-week Discontinuation Period. Informed consent will be obtained prior to performing any study-specific procedures. The Screening Visit will occur within 8 to 28 days prior to randomization to assess eligibility.

Registry

clinicaltrials.gov

Start Date

August 10, 2020

End Date

October 28, 2021

Last Updated

3 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Haisco Pharmaceutical Group Co., Ltd.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subjects who are willing to sign an informed consent form, fully understand the objectives and purposes of the study, and are willing to comply with the study protocol before any of the study-related procedures start;
•Aged ≥ 18 and ≤ 75 years old, male or female;
•Dry weight ≥ 50.0 kg at screening, body mass index (BMI = weight (kg) / height2 \[m2\]) in the range of 16.0-30.0 kg/m\^2 (inclusive);
•Patients with end-stage renal diseases who receive hemodialysis (including hemodiafiltration) 3 times in a week prior to screening for at least 3 months;
•Patients with at least two occurrences of single-compartment urea clearance (sp Kt/V, see Appendix 7 for the calculation formula) ≥ 1.2, or at least two occurrences of urea reduction ratio (URR) ≥ 65%, or one occurrence of sp Kt/V ≥ 1.2 and one occurrence of URR ≥ 65% on different days of dialysis within 3 months before screening;
•Male subjects must agree to use condoms in sexual intercourse during the study and within 3 months after the last dose; female subjects should have had menopause for at least one year, or should have had permanent sterilization (e.g., fallopian tube occlusion, hysterectomy, bilateral salpingectomy); or women of childbearing potential must agree to take effective contraceptive measures during the study and within 3 months after the last dose, such as oral contraceptives, condoms, and contraceptive films.

Exclusion Criteria

•Expected to undergo kidney transplantation and/or parathyroidectomy during the study;
•History of allergy to opioids, such as urticaria (Note: adverse effects related to opioid use, such as constipation and nausea, are not included as the exclusion criteria in this study);
•Used opioids within one week before screening, or unable to avoid the use of opioids other than the investigational product during the study;
•Participated in any clinical trial of other drug or medical device within 1 month before screening (received study medication or treated by the medical device in the clinical trial);
•Used blood perfusion within 3 months before screening;
•History of medication or drug abuse;
•Average daily alcohol consumption greater than 15 g (15 g of alcohol is equivalent to 450 mL of beer or 150 mL of wine or 50 mL of light liquor) within 3 months before screening;
•Unable to comply with the standard dietary plan and unable to avoid coffee or tea during the study;
•Blood pressure of upper limbs in the supine position at screening: systolic blood pressure \< 90 mmHg, or diastolic blood pressure \< 60 mmHg, or systolic blood pressure \> 180 mmHg, or diastolic blood pressure \> 110 mmHg;
•New York Heart Association (NYHA) Class ≥ III at screening; or confirmed to have abnormal ECG at screening and determined by the investigator to be inappropriate to be enrolled, including QTcF ≥ 480 ms;

Outcomes

Primary Outcomes

Stage II：At week 12, the change in weekly average of daily Worst Itch NRS (WI-NRS) from baseline in subjects undergoing hemodialysis

Time Frame: 12 week

Change from baseline in average NRS score of itch at week 12

Stage I：Safety of HSK21542 injection for multiple times within one week in hemodialysis subjects

Time Frame: From screening up to D14

Adverse events (AEs) and serious adverse events (SAEs)，Vital signs、Physical examination, Laboratory examination, ECG

Secondary Outcomes

Stage I：Time to the peak plasma concentration (Tmax)(1 week)
Stage I：Change from baseline in average daily Worst Itch NRS (WI-NRS) and Itch-related Quality of Life as Assessed by Skindex-16 Scale Score(1 week)
Stage II：Maximum Concentration (Cmax)(12 weeks)
Stage II：Total body clearance following intravenous administration (CL)(12 weeks)
Stage II: The proportion of subjects change from baseline ≥3 points with respect to the weekly mean of the daily 24-hour Worst Itching Intensity NRS Score at Week 12(12 week)
Stage I：Area under the plasma concentration versus time curve (AUC)(1 week)
Stage I：Maximum Concentration (Cmax)(1 week)
Stage I：Half-time (T1/2)(1 week)
Stage I：Total body clearance following intravenous administration (CL)(1 week)
Stage I：Volume of distribution following intravenous administration (Vss)(1 week)
Stage II：Half-time (T1/2)(12 weeks)
Stage II: Change from baseline in the level of serum IL-6，IL-31，TNF-α，and hs-CRP(12 weeks)
Stage I：trough concentration (Cmin)(1 week)
Stage II：Time to Maximum plasma concentration (Tmax)(12 weeks)
Stage I：Correlation between prolactin level and drug exposure of HSK21542 injection in hemodialysis subjects(1 week)
Stage II：Volume of distribution following intravenous administration (Vss)(12 weeks)
Stage II: Safety of HSK21542 injection in the treatment of moderate and severe pruritus in hemodialysis subjects for 12 weeks(12 weeks)
Stage II：Area under the plasma concentration versus time curve (AUC)(12 weeks)
Stage II: Weekly mean value of the ShOWS and OOWS Score within 2 weeks after drug withdrawal after 12 weeks of administration(14 week)
Stage II: The proportion of subjects change from baseline ≥4 points with respect to the weekly mean of the daily 24-hour Worst Itching Intensity NRS Score at Week 12(12 week)
Stage II: Weekly mean value of the daily 24-hour Worst Itching Intensity NRS Score within 2 weeks after drug withdrawal after 12 weeks of administration(14 week)
Stage II：Change from baseline in Itch-related Quality of Life as Assessed by Skindex-16 and 5-D Scale Score(12 week)
Stage II: Change from baseline in the level of serum iPTH(12 weeks)